Denosumab in the treatment of giant cell tumor of the spine. Preliminary report, review of the literature and protocol proposal
- 16 May 2019
- journal article
- review article
- Published by Springer Nature in European Spine Journal
- Vol. 29 (2) , 257-271
Abstract
The interest on the role of Denosumab in the treatment strategy of giant cell tumor of the spine is growing. En bloc resection is considered the Enneking appropriate treatment, but morbidity and functional loss are sometimes unacceptable. Denosumab could play a role as a stand-alone treatment, but also as preoperative treatment or as postoperative after intralesional surgery.Keywords
This publication has 55 references indexed in Scilit:
- Safety and efficacy of denosumab for adults and skeletally mature adolescents with giant cell tumour of bone: interim analysis of an open-label, parallel-group, phase 2 studyThe Lancet Oncology, 2013
- Denosumab Chemotherapy for Recurrent Giant-Cell Tumor of Bone: A Case Report of Neoadjuvant Use Enabling Complete Surgical ResectionCase Reports in Oncological Medicine, 2013
- Aggressive “Benign” Primary Spine NeoplasmsSpine, 2009
- Morbidity of en bloc resections in the spineEuropean Spine Journal, 2009
- Serial Arterial Embolization for Large Sacral Giant-Cell TumorsSpine, 2007
- Triple Total Cervical Vertebrectomy for a Giant Cell TumorSpine, 2005
- Giant Cell Tumor of the Pelvis and SacrumClinical Orthopaedics and Related Research, 2004
- Osteoclast differentiation and activationNature, 2003
- Surgical treatment of giant cell tumours of the thoracic and lumbar spine: report of nine patientsEuropean Spine Journal, 2001
- Giant Cell Tumor of BoneClinical Orthopaedics and Related Research, 1986